On September 30, 2024, over 400 professionals gathered for a symposium organized by the Finnish Biobank Cooperative- FINBB and Fingenious.
The symposium convened medical, biotechnology, and scientific professionals from around the globe, presenting a series of real-life cases in neurology, immunology, oncology, ophthalmology, and rare diseases.
The cases highlighted by international experts showcased the research opportunities available through Finnish biobanks, emphasizing the unique genetic heritage of the Finnish population as a model for target discovery in personalized medicine.
During the event, Erkki Soini, CEO of ESiOR, provided insights into a predictive analysis of clinical outcomes and cost-effectiveness for women aged 20 to 79 years who carry susceptible BRCA1, BRCA2, or PALB2 mutations, based on Finnish biobank samples. He compared the recall of these women to the current practice of no recall, focusing on mutations associated with hereditary breast and ovarian cancer.
Fingenious offers a comprehensive digital platform for academic and industry researchers worldwide, facilitating access to all public biobanks in Finland for biospecimen, data, and study participant discovery.
To view The Symposium recording, please visit here.
Additional information: Erkki Soini